Navigation Links
Novavax's VLP Influenza Vaccine Named One of Top 100 Drugs in Development Today
Date:4/5/2011

ROCKVILLE, Md., April 5, 2011 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX) announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today.  In its tenth annual list of promising clinical compounds, R&D Directions cited Novavax's virus-like-particle technology as a promising new approach to producing vaccines to prevent seasonal, H1N1 and avian influenza.  The list reflects the current interests of industry observers and analysts and is described in the magazine's March 2011 issue.

"We are honored to be recognized by editors and analysts who follow the pharmaceutical industry and gratified by their interest in our technology and vaccine candidates," said Dr. Rahul Singhvi, President and CEO of Novavax.  "Our recent BARDA contract award and new partnership with LG Life Sciences demonstrate the progress we are making and reflect the potential of our technology to revolutionize the development and production of influenza vaccines.  It is a very exciting time for our company and we appreciate this recognition of our work to prevent the spread of infectious diseases around the world."

About Novavax

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary VLP technology and single-use bioprocessing system enables rapid vaccine development and production where and when it's needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

Forward Looking Statements

Statements herein relating to the ongoing development of its VLP vaccine products, including references to Novavax contracts with HHS BARDA or LG Life Sciences, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements include: the Company has not yet manufactured, or relied on third parties to manufacture, any vaccines at a commercial scale; historical and current results may not be predictive of future trial results for the seasonal influenza vaccine or any other vaccine candidate; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if the results are similar or better than the results reported to date; HHS BARDA may or may not award any option period funding to Novavax; and additional factors, many of which are outside the company's control. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune to Present 11 Abstracts on Influenza at 45th Annual National Immunization Conference
2. Novavax Licenses Recombinant VLP Influenza Vaccine to LG Life Sciences for South Korea and Other Countries
3. NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting
4. NexBio’s DAS181 (Fludase®*) Improved Symptoms in a Severely Immunocompromised Patient with Parainfluenza Pneumonitis
5. NOVAVAX to Present H1N1 VLP Influenza Vaccine Clinical Data at 7th World Health Organization (WHO) Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials
6. American Lung Association Recognizes Older Adults Vaccination Day with Release of New Report Examining Disparities in Influenza and Pneumonia Vaccination Rates Among Older Americans
7. IDRI Awarded Contract from BARDA to Develop Next Generation Adjuvants for Pandemic Influenza
8. Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine
9. New Influenza Drug Inavir(R) TwinCaps(R) Launched in Japan
10. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
11. Hoviones TwinCaps(R) Dry-powder Inhaler Approved in Japan as Part of Inavir(R) Influenza Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , 12 februari 2016 AAIPharma ... toonaangevende leverancier van productie en ontwikkeling op ... kondigt vandaag een uitbreiding aan van steriele ... locatie in Charleston, SC ... tot meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/12/2016)... February 12, 2016 ... titled Chronic Inflammation Global Clinical Trials Review, H2, ... the global clinical trials landscape along with top ... Region, Country (G7 & E7), Trial Status, Trial ... reviews top companies involved and enlists all trials ...
(Date:2/11/2016)... , Feb. 11, 2016 Stem cells ... are characterized by self-renewal and the capacity to differentiate ... relatively new discovery, as the first mouse embryonic stem ... was not until 1995 that the first culturing of ... stem cells were not produced until 2006 As a ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, 2016. ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... life cycle of pharmaceutical products, garnering increased attention from all stakeholders in the ...
(Date:2/12/2016)... ... , ... As a former television executive, owner Tal Rabinowitz knows how stressful ... decompress, Rabinowitz found herself drawn to a casual meditation class while working at NBC ... implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, she ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., ... have closed for the ISE Southeast Awards 2016. Finalists and winners of the ... ISE® Southeast Executive Forum and Awards Gala on March 15, 2016 at the ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... a Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into ... partners to offer real-time business intelligence (BI) to their small and medium business ...
Breaking Medicine News(10 mins):